Medicus Pharma Ltd (NASDAQ:MDCX) Short Interest Update

Medicus Pharma Ltd (NASDAQ:MDCX) saw a significant increase in short interest in the month of July. As of July 15th, there was short interest totaling 2,838,930 shares, an increase of 171.5% from the June 30th total of 1,045,598 shares. Based on an average trading volume of 1,143,133 shares, the days-to-cover ratio is currently 2.5 days. Currently, 5.5% of the shares of the company are short sold.

Medicus Pharma Trading Down 12.0%

Medicus Pharma stock traded down $0.04 during trading on Tuesday, reaching $0.28. The company had a trading volume of 2,030,037 shares, compared to its average volume of 3,614,962. Medicus Pharma has a 52 week low of $0.25 and a 52 week high of $3.05. The firm’s 50-day simple moving average is $0.37 and its 200 day simple moving average is $0.64. The firm has a market capitalization of $15.86 million, a price-to-earnings ratio of -0.10 and a beta of -0.05.

Medicus Pharma (NASDAQ:MDCX) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.13). On average, analysts predict that Medicus Pharma will post -0.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on MDCX shares. D. Boral Capital restated a “buy” rating and set a $9.00 price target on shares of Medicus Pharma in a research note on Monday, April 20th. Roth Capital started coverage on shares of Medicus Pharma in a research note on Tuesday, April 21st. They issued a “buy” rating on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Medicus Pharma in a report on Wednesday, July 8th. Finally, Alliance Global Partners began coverage on shares of Medicus Pharma in a research report on Tuesday. They set a “buy” rating for the company. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Medicus Pharma currently has an average rating of “Hold” and an average price target of $9.00.

Institutional Investors Weigh In On Medicus Pharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new stake in Medicus Pharma during the 2nd quarter worth approximately $41,000. Osaic Holdings Inc. increased its stake in shares of Medicus Pharma by 180.0% in the second quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after purchasing an additional 9,000 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Medicus Pharma in the third quarter worth $59,000. HRT Financial LP bought a new stake in shares of Medicus Pharma during the 4th quarter valued at $42,000. Finally, Commonwealth Equity Services LLC lifted its stake in shares of Medicus Pharma by 161.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock valued at $44,000 after buying an additional 17,611 shares in the last quarter.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.